---
title: "Kangxin New Materials released its performance for the first three quarters, with a net loss attributable to the parent company of 189 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262879191.md"
description: "According to the Zhitong Finance APP, Kangxin New Materials disclosed its third-quarter report for 2025. The company achieved revenue of 278 million yuan in the first three quarters, a year-on-year decrease of 43.74%; the net profit attributable to shareholders was a loss of 189 million yuan; the net profit excluding non-recurring gains and losses was a loss of 196 million yuan; basic earnings per share were -0.14 yuan"
datetime: "2025-10-27T11:19:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262879191.md)
  - [en](https://longbridge.com/en/news/262879191.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262879191.md)
generator: "portal-rs"
---

# Kangxin New Materials released its performance for the first three quarters, with a net loss attributable to the parent company of 189 million yuan

According to the Zhitong Finance APP, Kangxin New Materials (600076.SH) disclosed its third-quarter report for 2025. The company achieved a revenue of 278 million yuan in the first three quarters, a year-on-year decrease of 43.74%; the net profit attributable to shareholders was a loss of 189 million yuan; the net profit excluding non-recurring gains and losses was a loss of 196 million yuan; the basic earnings per share were -0.14 yuan

### Related Stocks

- [600076.CN](https://longbridge.com/en/quote/600076.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [Cocoa Prices Fall on Rising Nigerian Cocoa Exports](https://longbridge.com/en/news/296637826.md)
- [03:20 ETMacGregor advances direct ship-to-well LCO₂ transfer, built on 50 years of proven bow-loading technology](https://longbridge.com/en/news/296749870.md)
- [CDC lifts beneficial stake in Exosens to 11.71% of capital, 13.87% of voting rights](https://longbridge.com/en/news/296499698.md)
- [Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate](https://longbridge.com/en/news/296689195.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**